**Table 1. Correlation of ACR CRSS with Change in Core Item, r**

<table>
<thead>
<tr>
<th>Time</th>
<th>mRSS</th>
<th>PIGA</th>
<th>HAQ-DI</th>
<th>MDGA</th>
<th>FVC% predicted</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 months</td>
<td>-0.91</td>
<td>-0.37</td>
<td>-0.45</td>
<td>-0.66</td>
<td>0.38</td>
</tr>
<tr>
<td>12 months</td>
<td>-0.76</td>
<td>-0.38</td>
<td>-0.39</td>
<td>-0.38</td>
<td>0.54</td>
</tr>
</tbody>
</table>

**Conclusion:** In the context of the lenabuzumab Phase 2 clinical trial, ACR CRSS core items at baseline and change in ACR core items were not redundant (r < 0.80). Change in each core item correlated with ACR CRSS score, indicating each contributed to the score at both 4 and 12 months. The 12-month median ACR CRSS score was higher in subjects with greater levels of improvement in PROs, even PRO that were not core items, showing that ACR CRSS score reflects long-term clinical benefit in how the patient feels and functions. These data provide preliminary evaluation of the ACR CRSS score as a clinical trial endpoint in dcSSc.

**Disclosure of Interests:** Robert Spiera Grant/research support from: Roche, Denk, Boehringer-Ingelheim, StallNet-MaxoSmithKline, Myers Squibb, Hana Biopharma, Mitsubishi-Tanabe, Astellas: Grant Review Board for Actelion, Speakers bureau: None declared, Marco Matucci-Cerinic Grant/research support from: Actelion, MSD, Pfizer, BMS, Chemomab, Sanipedia, Speakers bureau: Actelion, BMS, MSD; Janssen, Oliver Distler Grant/research support from: Prof. Distler received research funding from Actelion, Bayer, Boehringer Ingelheim and Mitsubishi Tanabe to investigate potential treatments of scleroderma and its complications, Consultant for: Prof. Distler has/had consultancy relationship within the last 3 years with Actelion, AnaMar, Bayer, Boehringer Ingelheim, ChemomAB, espeRare foundation, Genentech/Roche, GSK, Inventiva, Italfarmaco, iQvia, Lilly, medac, Medimmune, Mitsubishi Tanabe Pharma, Pharmacia, Novartis, Pfizer, Sanofi, Serodapharm and UCB in the area of potential treatments of scleroderma and its complications. In addition, he had/has consultancy relationship within the last 3 years with A. Menarini, Ajzen, Abibige, GSK, Mepha, MSD, Pfizer and UCB in the field of arthritis and related disorders, Ora Gewurz-Singer: None declared, David Fox Grant/research support from: Regeneron, Gilead, Seattle Genetics, Consultant for: Grant reviewer for Pfizer, Daniel Forst Grant/research support from: F. Hoffmann-La Roche, Genentech DOI: 10.1136/annrheumdis-2019-eular.3389

**WEDNESDAY, 12 JUNE 2019**

**Bringing digital health care solutions to patients**

Tinja Saarela. The Finnish Rheumatism Association, Helsinki, Finland

**Background:** The Finnish Rheumatism Association and Novartis started a project in 2017 to energise our local associations, members and their families by adapting an active lifestyle. Geocaching is a fun, family-friendly way to exercise and adapt an active lifestyle. Geocaching is a water proof container containing a book and sometimes a pen or pencil. The geocacher signs the log with their established code name and dates it to prove that they found the cache. After signing the log, the cache must be placed back exactly where it was found.

**Objectives:** The main goal of the project was to hide 70 new caches all over Finland to create an enjoyable experience for other geocachers. Those caches were named “Reumageo” at the beginning of the cachename. For all the associations that were involved in this project received money allocated to sport and physical activity out of the 15,000 euro project budget. The project ended on 12 October 2018, and all logged caches were included in the game.

**Results:** We started our project with association representatives. The training included the basics of geocaching: how to find caches, how to hide your cache and create your cache page, different geocaching pages and everything you should know geocaching. The trained representatives told about geocaching in their own associations, and they were responsible for creating at least 2-3 new caches and handling the new caches. The main idea was that when you have found about 15-20 caches you should start to hide your own caches. Together with local associations our aim was to create 70 caches all over Finland to celebrate the 70-year-old Finnish Rheumatism Association.

Outdoor geocaching adventure starts indoors with preparation and online research. You need a Global Positioning System (GPS) receiver or mobile device, your own account at the site geocaching.com. The site offers a completely free access to the caching data and all the site features. The site offers also a “premium” member status to access certain features. You can also download the Geocaching intro app onto your smartphone, like Geocaching.